Table 1.

Demographics and clinical data of 24 hospitalized LT recipients with COVID-19 in severe and non-severe groups

Variable	Non-severe N = 15	Severe N = 9	p-value
Age (mean ± SD)	45.67 ± 14.54	52.67 ± 11.11	0.228
Gender (male)	12 (80%)	4 (44.4%)	0.099
Past medical history
Diabetes	5 (33.3%)	1 (11.1%)	0.351
hypertension	2 (13.3%)	1 (11.1%)	1
Vaccination against COVID-19 (yes)	7 (46.6%)	3 (33.3%)	0.678
Smoking	1 (6.6%)	0	1
Interval since transplantation
Month (median)	7.87 ± 9.70	2.44 ± 5.57	0.068
Hospitalization period (days)	12.67 ± 9.53	24.33 ± 13.19	0.020*
Etiology of liver damage
Alcoholic hepatitis	1 (6.6%)	1 (11.1%)	1
Hepatitis B	2 (13.3%)	3 (33.3%)	0.326
Hepatitis C	1 (6.6%)	0	1
Wilson disease	1 (6.6%)	0	1
PSC	5 (33.3%)	2 (22.2%)	0.669
NASH	2 (13.3%)	2 (22.2%)	0.615
Others	3 (20%)	1 (11.1%)	1
Clinical presentation of COVID-19
Fever	3 (20%)	3 (33.3%)	0.635
Cough	4 (26.6%)	3 (33.3%)	1
Dyspnea	3 (20%)	4 (44.4%)	0.356
Headache	3 (20%)	1 (11.1%)	1
Gastrointestinal	5 (33.3%)	3 (33.3%)	1
Sore throat	3 (20%)	0	0.266
Others	3 (20%)	2 (22.2%)	1

*Statistically significant

LT, liver transplant; PSC, primary sclerosing cholangitis; NASH, non-alcoholic steatohepatitis